• Biopure
    substitute Derived from bovine hemoglobin  Transports oxygen to tissue  Oxyglobin - animal (dog)  Hemopure – human   Human version more refined  Clinical trials anticipated 2 Market Summary Animal blood substitute (Oxyglobin)  Available – 5,400,000 units  15,000 clinics * 800 cases...
    Premium 1275 Words 6 Pages
  • Biopure
    Problem – Question #6 Biopure’s main concern about an immediate launch of Oxyglobin is its possibly negative effect on the eventual pricing of Hemopure. If Biopure were to decide to launch Oxyglobin now, an appropriate marketing mix would target those market segments with the greatest need...
    Premium 437 Words 2 Pages
  • Biopure
    market Oxyglobin, and whether to launch it concurrently or separately from Hemopure. In addition to these issues, questions exist regarding the pricing of Oxyglobin if it is launched prior to Hemopure, and what veterinarians the initial marketing strategy should focus on. How to market Oxyglobin is contingent...
    Premium 666 Words 3 Pages
  • Biopure Case
    pharmaceuticals that are intravenously administered to deliver oxygen to the body's tissues. Biopure's two products, Hemopure for human use, and Oxyglobin for animal veterinary use, both represented a new Oxygen based treatment approach for managing patients' oxygen requirements in a broad range of potential...
    Premium 1638 Words 7 Pages
  • Corporate Finance
    biopharmaceutical company that specializes in synthesis of blood substitute for both human use and animal use. Biopure’s blood substitute for veterinary use, Oxyglobin, has received FDA approval for large scale synthesis and selling, while Biopure’s blood substitute for Human use, Hemopure, is yet to receive the...
    Premium 1632 Words 7 Pages
  • Biopure Solution
    Course: Strategic Marketing Management Name: Firat Sekerli The Problem: Biopure Corporation has two new products that are Oxyglobin and Hemopure. Oxyglobin is the first new blood substitute for the veterinary market and is ready for consumer use. Hemopure is another new blood substitute for...
    Premium 672 Words 3 Pages
  • Biopure Case Study
    Biopure Corporation have two new products that are Oxyglobin and Hemopure. Oxyglobin is the first blood substitute for the veterinary market and is ready for launch. Hemopure is another new blood substitute for the human market and will take two years to launch. Ted Jacobs, VP (Human Clinical Trials)...
    Premium 718 Words 3 Pages
  • Oxyglobin
    Yanping Chen Oxyglobin should be the first There were some debates of marketing strategy made the management level of Biopure very headache. Should Oxyglobin been introduced to the market earlier than Hemopure? Andy Wright , vice president for veterinary products said Yes. While Ted...
    Premium 1770 Words 8 Pages
  • Corporate Finance
    biopharmaceutical company that specializes in synthesis of blood substitute for both human use and animal use. Biopure’s blood substitute for veterinary use, Oxyglobin, has received FDA approval for large scale synthesis and selling, while Biopure’s blood substitute for Human use, Hemopure, is yet to receive the...
    Premium 1632 Words 7 Pages
  • Biopure Case Study Report
    Summary * Biopure Corporation developed two new products to enter into the field of blood substitutes: Hemopure, directed to the human market and Oxyglobin, for the veterinary market. Through the end of 1997 no blood substitute had received approval for use anywhere in the world. * What distinguishes...
    Premium 2663 Words 11 Pages
  • Marketing
    Biopure was grappling with the decision to launch Oxyglobin immediately versus delaying the launch after the Hemopure product was approved and established in the market. Proponents of the “launch now” view argue that the company would benefit from the Oxyglobin revenues; capital that could be used toward the...
    Premium 794 Words 4 Pages
  • Biopure Case
    of whether it should release one of its products or not. The product is named Oxyglobin, and it is designed as a blood substitute for small animals. The key issue here is whether to release or not; and if release, what price to charge and how to distribute. After research and analyze carefully about the...
    Premium 2040 Words 9 Pages
  • Biopure Case
    immediately launch Oxyglobin rather than wait for Hemopure's FDA Approval then launch both products simultaneously. The proposed price for Oxyglobin is $300 per unit with promotion campaign from time to time. With this set price of immediate launch, Biopure will reach breakeven point for Oxyglobin in year 2000...
    Premium 7016 Words 29 Pages
  • Biopure notes
    Potential – 1,749,375 units a. Set price at $100, lower prices would result in a loss to Biopure b. Percentage of Vets willing to use * Percentage of Owners willing to use * number of dogs that would benefit * 1.5 units per dog 3. Target – 249,750 units a. Set price at $200 i. Maximize profit ii....
    Premium 1103 Words 5 Pages
  • Biopure Case Study
    key issue is to determine when Oxyglobin should be introduced to the market without jeopardizing Hemopure’s potential and how it should be marketed. In addressing the issue, the following were considered: a sensitivity analysis for potential consumption of different price series, associated revenues...
    Premium 935 Words 4 Pages
  • Biopure
     Brief Overview: Biopure has two new products namely Oxyglobin and Hemopure. Oxyglobin is a first of its kind, new blood substitute for the veterinary market and has passed all the tests and is ready for consumer use. Hemopure is another such blood substitute for the human market and it will take...
    Premium 1060 Words 5 Pages
  • Biopure’s Case Study
    market is the pricing for Oxyglobin. It is the dilemma to price Oxglobin. If the price is too high, pet owners will not accept to use Oxglobin to treat the pet. Moreover, vets tend to use simple and cheaper way to treat pet if Oxglobin is priced to high. However, if Oxglobin price is low, vets may not consider...
    Premium 804 Words 4 Pages
  • Biopure case memo
    CARL RAUSCH, CEO, BIOPURE FROM: XXXXXXXXXX, MARKETING ANALYST, BIOPURE SUBJECT: OXYGLOBIN LAUNCH DATE: 50 4/22/2010 This memorandum is to propose that Biopure prepare to launch Oxyglobin as quickly as possible. The product should be priced at approximately $150 per unit and be...
    Premium 451 Words 2 Pages
  • Biopure Corporation
    Mishra, Ravi RE: Whether and When to Launch Oxyglobin Biopure needs to determine the best course of action to launch two new products, Oxyglobin a blood substitute for the veterinary market and Hemopure a blood substitute for the human market. Oxyglobin has been approved for commercial use and is...
    Premium 979 Words 4 Pages
  • Biopure Case Analysis
    Brief Overview: Biopure has two new products namely Oxyglobin and Hemopure. Oxyglobin is a first of its kind, new blood substitute for the veterinary market and has passed all the tests and is ready for consumer use. Hemopure is another such blood substitute for the human market and it will take a minimum...
    Premium 1200 Words 5 Pages